These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23213304)

  • 1. Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients.
    Huang Y; Ye S; Cao Y; Li Z; Huang J; Huang H; Cai M; Luo R; Lin T
    ScientificWorldJournal; 2012; 2012():897178. PubMed ID: 23213304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
    Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
    Bantilan KS; Smith AN; Maurer MJ; Teruya-Feldstein J; Matasar MJ; Moskowitz AJ; Straus DJ; Noy A; Palomba ML; Horwitz SM; Hamlin PA; Portlock CS; Cerhan JR; Habermann TM; Salles GA; Nowakowski GS; Moskowitz CH; Zelenetz AD
    Blood Adv; 2024 May; 8(9):2172-2181. PubMed ID: 38271621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.
    Huang X; Meng B; Iqbal J; Ding BB; Perry AM; Cao W; Smith LM; Bi C; Jiang C; Greiner TC; Weisenburger DD; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Gascoyne RD; Cook JR; Tubbs RR; Jaffe ES; Armitage JO; Vose JM; Staudt LM; McKeithan TW; Chan WC; Ye BH; Fu K
    J Clin Oncol; 2013 Dec; 31(36):4520-8. PubMed ID: 24220563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
    Vassilakopoulos TP; Pangalis GA; Katsigiannis A; Papageorgiou SG; Constantinou N; Terpos E; Zorbala A; Vrakidou E; Repoussis P; Poziopoulos C; Galani Z; Dimopoulou MN; Kokoris SI; Sachanas S; Kalpadakis C; Dimitriadou EM; Siakantaris MP; Kyrtsonis MC; Dervenoulas J; Dimopoulos MA; Meletis J; Roussou P; Panayiotidis P; Beris P; Angelopoulou MK
    Oncologist; 2012; 17(2):239-49. PubMed ID: 22282906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.
    Ji D; Li Q; Cao J; Guo Y; Lv F; Liu X; Wang B; Wang L; Luo Z; Chang J; Wu X; Hong X
    Oncotarget; 2016 May; 7(22):33331-9. PubMed ID: 27129176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.
    de Witt P; Maartens DJ; Uldrick TS; Sissolak G
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):66-73. PubMed ID: 23797692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Retrospective Study of R±DHAX Regimen versus R-CHOP Regimen First-Line Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma].
    Wei WP; Yu XQ; Wang LX; Zhang S; Fei XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):718-722. PubMed ID: 38926958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma.
    Huo Z; Chen F; Zhao J; Liu P; Chao Z; Liu K; Zhou J; Zhou D; Zhang L; Zhen H; Yang W; Tan Z; Zhu K; Luo Z
    Clin Exp Med; 2023 Dec; 23(8):4665-4672. PubMed ID: 37938466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
    Johnson NA; Boyle M; Bashashati A; Leach S; Brooks-Wilson A; Sehn LH; Chhanabhai M; Brinkman RR; Connors JM; Weng AP; Gascoyne RD
    Blood; 2009 Apr; 113(16):3773-80. PubMed ID: 19029441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL.
    Abdelhamid TM; Gaber AA; Abdelfattah RM; Algamal DA; Hamdy O; Mohamed G
    Pathol Res Pract; 2024 Jan; 253():154973. PubMed ID: 38101156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma: A STROBE-compliant article.
    Zhang Y; Wei Z; Li J; Gao R; Liu P
    Medicine (Baltimore); 2018 Jul; 97(30):e11719. PubMed ID: 30045337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
    Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
    Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Chen Q; Staton AD; Ayer T; Goldstein DA; Koff JL; Flowers CR
    Leuk Lymphoma; 2018 Jul; 59(7):1700-1709. PubMed ID: 29065744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases.
    Sugitani A; Fukuhara S; Shibata M; Ichihara R; Furukawa H; Maeshima AM
    J Clin Exp Hematop; 2023 Sep; 63(3):181-186. PubMed ID: 37518270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
    Hartert KT; Wenzl K; Krull JE; Manske M; Sarangi V; Asmann Y; Larson MC; Maurer MJ; Slager S; Macon WR; King RL; Feldman AL; Gandhi AK; Link BK; Habermann TM; Yang ZZ; Ansell SM; Cerhan JR; Witzig TE; Nowakowski GS; Novak AJ
    Leukemia; 2021 Feb; 35(2):522-533. PubMed ID: 32139889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
    Desai SH; Mwangi R; Smith AN; Maurer MJ; Farooq U; King RL; Cerhan JR; Feldman AL; Habermann TM; Thompson CA; Wang Y; Ansell SM; Witzig TE; Nowakowski GS
    Hematol Oncol; 2023 Feb; 41(1):39-49. PubMed ID: 36305717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era.
    Sofo-Hafizovic A; Chikha A; Gojak R; Hadzimesic ES
    Med Arch; 2016 Oct; 70(5):342-347. PubMed ID: 27994293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Characteristics and Prognosis of Patients with Primary Testicular Diffuse Large B-Cell Lymphoma].
    Zhang XL; Yu WJ; Zhu YN; Xu HL; Yang CM; Xiao F; Mai WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1372-1378. PubMed ID: 37846687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.